A. Wagner

发表

Methods for estimating confidence intervals in interrupted time series analyses of health interventions.

Fang Zhang, Anita K Wagner, Dennis Ross-Degnan, 2009, Journal of clinical epidemiology.

Article 1: Supervision, Performance Assessment, and Recognition Strategy (SPARS) - a multipronged intervention strategy for strengthening medicines management in Uganda: method presentation and facility performance at baseline

A. Wagner, B. Trap, M. Oteba, 2016, Journal of pharmaceutical policy and practice.

Impacts of a new insurance benefit with capitated provider payment on healthcare utilization, expenditure and quality of medication prescribing in China

Xiaotian Zhang, D. Ross-Degnan, H. Hogerzeil, 2016, Tropical medicine & international health : TM & IH.

Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending

Luwen Shi, A. Wagner, X. Guan, 2021, Cancer communications.

Essential medicines for universal health coverage

M. Reich, D. Ross-Degnan, A. Rashidian, 2019 .

Essential medicines for universal health coverage

M. Reich, D. Ross-Degnan, A. Rashidian, 2016, The Lancet.

Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer

Christine Y. Lu, C. Earle, D. Ross-Degnan, 2016, Breast Cancer Research and Treatment.

The Complex Cancer Care Coverage Environment — What is the Role of Legislation? A Case Study from Massachusetts

Christine Y. Lu, A. Wagner, C. Leopold, 2020, Journal of Law, Medicine & Ethics.

Defining Value of Cancer Therapeutics-A Health System Perspective.

J. Peppercorn, A. Wagner, S. Y. Zafar, 2018, Journal of the National Cancer Institute.

A rapidly changing global medicines environment: How adaptable are funding decision-making systems?

S. Morgan, A. Wagner, C. Leopold, 2017, Health policy.

Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence.

D. Ross-Degnan, Laura B Faden, A. Wagner, 2011, Health policy.

Prescribing for acute childhood infections in developing and transitional countries, 1990–2009

D. Ross-Degnan, K. Holloway, A. Wagner, 2015, Paediatrics and international child health.

Have we improved use of medicines in developing and transitional countries and do we know how to? Two decades of evidence

D. Ross-Degnan, K. Holloway, A. Wagner, 2013, Tropical medicine & international health : TM & IH.

Article 3: 1-year impact of supervision, performance assessment, and recognition strategy (SPARS) on prescribing and dispensing quality in Ugandan health facilities

D. Ross-Degnan, A. Wagner, B. Trap, 2020, Journal of Pharmaceutical Policy and Practice.

Medication Use During Pregnancy in Mainland China: A Cross-Sectional Analysis of a National Health Insurance Database

C. Ung, Luwen Shi, A. Wagner, 2019, Clinical epidemiology.

FDA drug prescribing warnings: is the black box half empty or half full?

Robert L Davis, Richard Platt, Marsha A Raebel, 2006, Pharmacoepidemiology and drug safety.

Out-of-Pocket Burden of Health Care Spending and the Adequacy of the Medicare Part D Low-Income Subsidy

J. Gurwitz, S. Soumerai, B. Briesacher, 2010, Medical care.

Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs.

H. Naci, S. Woloshin, Ziyue Xu, 2021, JAMA internal medicine.

A descriptive review of the methodologies used in household surveys on medicine utilization

A. Barros, P. Hallal, A. D. Bertoldi, 2008, BMC health services research.

Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand

Christine Y. Lu, D. Ross-Degnan, N. Chaiyakunapruk, 2015, PloS one.

Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States

S. Gupta, A. Denburg, A. L. Frazier, 2021, International journal of cancer.

Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program

M. Gilkey, A. Wagner, C. Leopold, 2019, PharmacoEconomics - Open.

Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment.

Christine Y. Lu, C. Earle, S. Soumerai, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Forecasting essential childhood cancer drug need: An innovative model‐based approach

S. Gupta, Jennifer M Yeh, A. Denburg, 2021, Cancer.

A New Measure of Medication Affordability

J. Gurwitz, B. Briesacher, D. Ross-Degnan, 2009, Social work in public health.

Session 1A — Patient perspectives

C. Sitthi-amorn, D. Ross-Degnan, A. Wagner, 2008 .

Quality Reporting by Payers: A Mixed-Methods Study of Provider Perspectives and Practices

D. Ross-Degnan, M. Hoefer, A. Sinaiko, 2018, Quality management in health care.

Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey.

D. Ross-Degnan, Fang Zhang, R. Lecates, 2011, Health policy.

Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand

Christine Y. Lu, A. Wagner, C. Leopold, 2020, BMC Health Services Research.

Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces

D. Ross-Degnan, Shenglan Tang, A. Wagner, 2010, BMC health services research.

Medicines coverage and community-based health insurance in low-income countries

D. Ross-Degnan, J. Ntaganira, A. Wagner, 2008, Health research policy and systems.

The Effectiveness of Enhanced Primary Healthcare (EnPHC) interventions on Type 2 diabetes management in Malaysia: Difference-in-differences (DID) analysis.

Swee Hung Ang, R. Atun, D. Ross-Degnan, 2021, Primary care diabetes.

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020

Ziyue Xu, H. Naci, J. Ji, 2022, JAMA network open.

The Brazilian private pharmaceutical market after the first ten years of the generics law

A. D. Bertoldi, D. Ross-Degnan, P. Stephens, 2019, Journal of pharmaceutical policy and practice.

Measuring adherence to antiretroviral treatment in resource-poor settings: The clinical validity of key indicators

D. Ross-Degnan, H. Tadeg, Fang Zhang, 2010, BMC health services research.

Urgent need for coordination in adopting standardized antiretroviral adherence performance indicators.

D. Ross-Degnan, G. Tomson, R. Wahlström, 2010, Journal of acquired immune deficiency syndromes.

An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries.

S. Morgan, P. Bach, C. Good, 2018, Health policy.

Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States.

D. Ross-Degnan, J. Wharam, A. Wagner, 2020, JCO oncology practice.

Thirty Years of Media Coverage on High Drug Prices in the United States--A Never-Ending Story or a Time for Change?

J. Chambers, A. Wagner, C. Leopold, 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage

S. Morgan, A. Wagner, C. Leopold, 2017, Canadian Medical Association Journal.

Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.

B. Gyawali, H. Naci, D. Ross-Degnan, 2021, JAMA internal medicine.

Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval.

H. Naci, A. Wagner, Mahnum Shahzad, 2021, JAMA internal medicine.

Segmented regression analysis of interrupted time series studies in medication use research

A K Wagner, S B Soumerai, F Zhang, 2002, Journal of clinical pharmacy and therapeutics.

Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines

D. Ross-Degnan, A. Graves, A. Wagner, 2008, BMC health services research.

Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.

B. Gyawali, Luwen Shi, A. Wagner, 2021, Seminars in oncology.

Persistent postoperative pain, health-related quality of life, and functioning 1 month after hospital discharge

W. Rogers, S. Strassels, D. Carr, 2004 .

Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies

Fang Zhang, Ching-Lan Cheng, Anita K Wagner, 2015, Journal of pharmaceutical policy and practice.

Need for and Access to Health Care and Medicines: Are There Gender Inequities?

D. Ross-Degnan, Fang Zhang, A. Graves, 2013, PloS one.

Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.

M. Jiang, D. Ross-Degnan, Yu Fang, 2013, The Lancet. Global health.

Simulation-based power calculation for designing interrupted time series analyses of health policy interventions.

Fang Zhang, Anita K Wagner, Dennis Ross-Degnan, 2011, Journal of clinical epidemiology.

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China

Luwen Shi, A. Wagner, Sheng Han, 2021, BMJ Global Health.

Household expenditures for medicines and the role of free medicines in the Brazilian public health system.

A. Barros, P. Hallal, D. Ross-Degnan, 2011, American journal of public health.

Medicine access and utilization in a population covered by primary health care in Brazil.

Dennis Ross-Degnan, Pedro Curi Hallal, P. Hallal, 2009, Health policy.

Quality use of medicines within universal health coverage: challenges and opportunities

J. Quick, D. Ross-Degnan, A. Wagner, 2014, BMC Health Services Research.

Benzodiazepine use and hip fractures in the elderly: who is at greatest risk?

R. Glynn, J. Gurwitz, S. Soumerai, 2004, Archives of internal medicine.

Impact of universal health insurance coverage in Thailand on sales and market share of medicines for non-communicable diseases: an interrupted time series study

D. Ross-Degnan, P. Stephens, A. Wagner, 2012, BMJ Open.

Health insurance systems in five Sub-Saharan African countries: medicine benefits and data for decision making.

Anita K Wagner, Dennis Ross-Degnan, D. Ross-Degnan, 2011, Health policy.

Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries.

D. Ross-Degnan, B. Serumaga, A. Wagner, 2015, Health policy and planning.

Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans

Christine Y. Lu, C. Earle, D. Ross-Degnan, 2018, Breast Cancer Research and Treatment.

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries

Sabine Vogler, Anita K Wagner, Dennis Ross-Degnan, 2014, Bulletin of the World Health Organization.

A new analytic tool developed to assess safe use recommendations

N. Cocoros, J. Major, K. Haynes, 2019, Pharmacoepidemiology and drug safety.

Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.

S. Morgan, S. Vogler, A. Wagner, 2017, Health policy.

Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan

Christine Y. Lu, Ching-Lan Cheng, D. Ross-Degnan, 2015, Pharmacoepidemiology and drug safety.

How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?

Christine Y. Lu, D. Ross-Degnan, Fang Zhang, 2015, Clinical therapeutics.

Health care payments in the asia pacific: validation of five survey measures of economic burden

A. Zaslavsky, S. Soumerai, D. Ross-Degnan, 2013, International Journal for Equity in Health.

Improving Access to Medicines in Low and Middle Income Countries: Corporate Responsibilities in Context

K. Leisinger, A. Wagner, Laura F. Garabedian, 2012, Southern med review.

Effect of New York State Regulatory Action on Benzodiazepine Prescribing and Hip Fracture Rates

Fang Zhang, Dennis Ross-Degnan, J. Gurwitz, 2007, Annals of Internal Medicine.

Effects of state surveillance on new post-hospitalization benzodiazepine use.

S. Soumerai, D. Ross-Degnan, L. Cosler, 2003, International journal for quality in health care : journal of the International Society for Quality in Health Care.

State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.

Christine Y. Lu, Fang Zhang, A. Wagner, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer

Dennis Ross-Degnan, Larissa Nekhlyudov, Anita K. Wagner, 2011, Breast Cancer Research and Treatment.

Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.

Christine Y. Lu, M. Lai, K. Chan, 2014, Health policy.

Benzodiazepines and Hip Fractures

J. Gurwitz, S. Soumerai, D. Ross-Degnan, 2007 .

Using health markets to improve access to medicines: three case studies

D. Peters, A. Ghaffar, Z. Babar, 2016, Journal of pharmaceutical policy and practice.

Newly approved cancer drugs in China — innovation and clinical benefit

A. Wagner, X. Guan, Yichen Zhang, 2023, Nature Reviews Clinical Oncology.

Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses

D. Ross-Degnan, A. Mantel‐Teeuwisse, S. Vogler, 2014, International Journal for Equity in Health.

Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis

Christine Y. Lu, D. Ross-Degnan, T. Dhippayom, 2016, BMJ Open.

Does access to medicines differ by gender? Evidence from 15 low and middle income countries.

D. Ross-Degnan, P. Stephens, A. Wagner, 2013, Health policy.

Patient access schemes in Asia-pacific markets: current experience and future potential

Christine Y. Lu, D. Ross-Degnan, Z. Babar, 2015, Journal of pharmaceutical policy and practice.

Competency in supportive supervision: a study of public sector medicines management supervisors in Uganda

A. Wagner, B. Trap, M. Embrey, 2017, Journal of Pharmaceutical Policy and Practice.

Pharmaceutical system strengthening in Uganda: implementing a holistic, evidence-informed, long-term strategy

A. Wagner, B. Trap, M. Oteba, 2018, Journal of Pharmaceutical Policy and Practice.

Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe

H. Naci, A. Pokorny, B. Mintzes, 2023, BMJ.

Evaluation of Switching Patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs

J. Gagne, Wenlei Jiang, Yueqin Zhao, 2018, Drug Safety.

Differences in reimbursement listing of anticancer therapies in China: an observational study

D. Ross-Degnan, Luwen Shi, A. Wagner, 2020, BMJ Open.

How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study.

Yuanli Liu, Jing Sun, Yan Wang, 2019, Journal of global health.

Potentially Inappropriate Medication Use by Elderly Persons in U.S. Health Maintenance Organizations, 2000–2001

J. Gurwitz, S. Simon, A. Feldstein, 2005, Journal of the American Geriatrics Society.

What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool

S. Gupta, A. Denburg, Z. Ward, 2020, BMJ Open.

Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer

Christine Y. Lu, C. Earle, D. Ross-Degnan, 2018, Breast Cancer Research and Treatment.

Efficacy and costs of spinal muscular atrophy drugs

Jonathan J. Darrow, A. Wagner, Monica Sharma, 2020, Science Translational Medicine.

Evaluating quality of care for patients with type 2 diabetes using electronic health record information in Mexico

Michael Law, Dennis Ross-Degnan, Jorge Escobedo, 2012, BMC Medical Informatics and Decision Making.

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study

D. Ross-Degnan, Luwen Shi, A. Wagner, 2019, BMJ Open.

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis

H. Naci, Elias Mossialos, S. Vogler, 2023, Lancet regional health. Americas.

Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand

Christine Y. Lu, D. Ross-Degnan, P. Stephens, 2015, Journal of pharmaceutical policy and practice.

Changes in use of antidiabetic medications following price regulations in China (1999–2009)

Christine Y. Lu, D. Ross-Degnan, P. Stephens, 2013 .

Forecasting global essential childhood cancer drug need and cost: An innovative model-based approach.

S. Gupta, A. Denburg, Z. Ward, 2020 .

Patterns, appropriateness, and predictors of antimicrobial prescribing for adults with upper respiratory infections in urban slum communities of Bangkok.

C. Sitthi-amorn, D. Ross-Degnan, A. Wagner, 2005, The Southeast Asian journal of tropical medicine and public health.

Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway.

H. Naci, A. Wagner, Mahnum Shahzad, 2023, JAMA.

Use of Palliative Care Among Commercially Insured Patients With Metastatic Cancer Between 2001 and 2016

D. Ross-Degnan, M. Twaddle, J. Wharam, 2022, JCO oncology practice.

Cost burden of hepatitis C virus treatment in commercially insured patients.

Christine Y. Lu, D. Ross-Degnan, Fang Zhang, 2019, The American journal of managed care.

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data

Luwen Shi, A. Wagner, X. Guan, 2023, Journal of global health.

Pharmaceutical donations by the USA: an assessment of relevance and time-to-expiry.

M. Reich, A. Wagner, A. Wagner, 1999, Bulletin of the World Health Organization.

Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.

M. Jiang, D. Ross-Degnan, Yu Fang, 2013, Lancet Global Health.

Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines

D. Ross-Degnan, A. Graves, A. Wagner, 2008, BMC health services research.

Thirty Years of Media Coverage on High Drug Prices in the United States--A Never-Ending Story or a Time for Change?

J. Chambers, A. Wagner, C. Leopold, 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.